Rising prevalence of infectious disease, product launches, increasing strategic developments such as partnerships and agreements, rising government initiative program, increasing healthcare expenditure and increased resistance to existing therapies are key factors contributing to high CAGR of live vaccines during forecast period.
According to the current analysis of Reports and Data, the global Live Vaccines market was valued at USD 15.15 billion in 2018 and is expected to reach USD 24.95 billion by the year 2026, at a CAGR of 6.6%. Live vaccines are derived from disease causing viruses or bacterial strains, these diseases causing bodies are attenuated or weekend by repeated culturing, which is then replicates into the individual body once is injected in response body develops immune and targets the infectious disease. The live vaccines market is driven due to the increasing prevalence of infectious disease such as typhoid, across the globe. As per an estimation, around 11-21 million new cases of typhoid are registered worldwide. Approximately 10.0 million cases across the globe, were diagnosed with tuberculosis in 2017. Rising awareness among the public as well as favorable government initiatives is supporting the market growth in developing nations. For example, Indian government started Pulse Polio in India, which aims to approach 100% population irrespective of literacy, financial capability, and to all geographical regions of India by aiming majorly social media. Global Polio Eradication Initiative (GEPI) funds are managed by various public and private sector donors. Furthermore, according to the recent news, England is no more measles free state due to approximately 931 new cases were registered in England and Wales in 2018 and around 231 new cases in England were diagnosed with measles in the first quarter of 2019. The global burden of such diseases is contributing towards the growth of live vaccines market.
The global pharma healthcare market revenue growth is mainly driven by factors such as increasing research development activities in the healthcare sector, rapid adoption of digital technologies, growing demand for advanced point-of-care diagnostics, and rising trends of telehealth and telemedicine. The COVID-19 pandemic has led to acute healthcare supply shortage, and rapid spread of the SARS-CoV-2 infection and rising government initiatives to develop COVID-19 vaccines have further driven market revenue growth.
To get a sample copy of the report, click on @ https://www.reportsanddata.com/sample-enquiry-form/2078
Top companies profiled in the report:
Merck Co., GlaxoSmithKline plc., Pfizer Inc., Astellas Pharma Inc., Emergent BioSolutions, AstraZeneca plc, Serum Institute of India Pvt. Ltd., Bharat Biotech, Sun Pharmaceutical Industries Limited, and Cipla Limited
Global Live Vaccines Market: Regional Outlook
- North America
- S.
- Canada
- Europe
- K.
- Germany
- France
- Italy
- Spain
- Asia Pacific
- India
- China
- Japan
- Australia
- Rest of Asia Pacific
- Latin America
- Brazil
- Argentina
- Peru
- Mexico
- Rest of Latin America
- Middle East Africa
- Saudi Arabia
- South Africa
- A.E
- Rest of Middle East Africa
Global Live Vaccines Market Segmentation:
Type Outlook (Revenue, USD Million; 2016-2026)
- Viral
- Bacterial
Route of Administration Outlook (Revenue, USD Million; 2016-2026)
- Oral
- Injection
- Intra-Nasal
- Combination of Injection and Oral
- Patch
- Inhalation
Application Outlook (Revenue, USD Million; 2016-2026)
- Measles
- Mumps
- Rubella
- Varicella
- Yellow Fever
- Rotavirus
- BCG
- Vaccinia
- Influenza
- Typhoid
- Oral Polio
- Smallpox
- Chickenpox
- Others
Patient Use Outlook (Revenue, USD Million; 2016-2026)
- Adults
- Children
To get a Order on the report, click on: @ https://www.reportsanddata.com/report-pricing/2078
Further key findings from the report suggest
- During 2019-2026, live vaccines market is expected to register a CAGR of 2% in Asia Pacific; followed by North America and Europe, with 6.4% and 6.5% CAGR, respectively. High prevalence of infectious diseases across the globe is the major factor driving the market during the forecast period across all regions.
- The measles segment dominates the market with a 24.8% market share in the year 2018. It is estimated to grow at a CAGR of 7.1% during the forecast period to reach USD 6.41 billion by 2026, as more number of patients are suffering from measles
- The injection route for the administration of live vaccines segment is forecasted to be the fastest growing market segment, estimated to witness a CAGR of 6.8%. Parenteral route or injection for the administration is required for vaccines that cannot be administered orally, due to the factors such as destruction of vaccine by digestive enzymes.
- Based on type, the viral type of live vaccines segment dominates the market holding over 60% market share.
- Asia Pacific accounted for the USD 3.44 billion of the global live vaccines market. Developing nations such China, and India are likely to witness high growth due to high population growth, high geriatric population in the region, and high prevalence of target diseases in the region
Request customization of the report @ https://www.reportsanddata.com/request-customization-form/2078
Thank you for reading our report. Do connect with us in case of any more queries about the report and its customization. Our team will ensure the report is well suited to cater to your needs.
About Reports and Data
Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target and analyze consumer behavior shifts across demographics, across industries and help client’s make a smarter business decision. We offer market intelligence studies ensuring relevant and fact-based research across a multiple industries including Healthcare, Technology, Chemicals, Power and Energy. We consistently update our research offerings to ensure our clients are aware about the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise.
Contact Us:
John W
Head of Business Development
Reports and Data | Web: www.reportsanddata.com
Direct Line: +1-212-710-1370
E-mail: sales@reportsanddata.com
